Full text
Earnings transcript
Read the complete earnings call transcript.
CVS
CVS Health Corporation
$97.06
-0.02
(-0.02%)
| Exchange: | NYSE |
| Market Cap: | 123.842B |
| Shares Outstanding: | 433.196M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Healthcare Plans | |||||
| CEO: | J. David Joyner | |||||
| Full Time Employees: | 300000 | |||||
| Address: |
| |||||
| Website: | https://www.cvshealth.com |
CVS Health Corporation is a prominent healthcare services provider operating across the United States. The company’s Health Care Benefits division delivers a range of health insurance offerings, including traditional plans, voluntary coverage, and consumer-directed options, alongside associated services. Its diverse clientele spans employer organizations, private individuals, university students, part-time and hourly staff, various health plans, healthcare providers, government bodies, state-sponsored programs, labor unions, and individuals living abroad. Through its Pharmacy Services segment, CVS Health manages pharmacy benefits, offering comprehensive solutions such as designing and administering plans, managing drug formularies, overseeing retail pharmacy networks, and providing mail-order, specialty pharmacy, and infusion services. This segment also delivers clinical support and helps manage disease and medical expenditures. It serves a broad array of clients, including employers, insurance carriers, trade unions, government employee groups, health plans, prescription drug programs, Medicaid managed care organizations, and plans available on both public and private health insurance marketplaces, in addition to other health benefit plan sponsors and individual consumers. Operationally, this segment encompasses specialty retail pharmacies, specialty mail-order services, general mail-order dispensing pharmacies, compounding pharmacies, and facilities dedicated to infusion and enteral nutrition support. The Retail/LTC (Long-Term Care) segment is responsible for selling both prescription and over-the-counter medications, consumer health and beauty items, and personal care products. It also delivers healthcare services via its MinuteClinic walk-in medical clinics. Furthermore, this segment handles the distribution of prescription drugs and offers pharmacy consulting along with other supplementary services to long-term care facilities and various other care environments. As of December 31, 2021, CVS Health boasted approximately 9,900 retail outlets and 1,200 MinuteClinic locations. This network is complemented by online retail pharmacy platforms, LTC pharmacies, and on-site pharmacies. Originally established in 1963 and headquartered in Woonsocket, Rhode Island, the company was known as CVS Caremark Corporation before officially rebranding to CVS Health Corporation in September 2014.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 357,776,000 | 372,809,000 | 402,067,000 |
| Gross Profit | 54,431,000 | 51,401,000 | 55,362,000 |
| EBITDA | 18,197,000 | 13,683,000 | 9,861,000 |
| Operating Income | 13,743,000 | 8,516,000 | 10,385,000 |
| Net Income | 8,344,000 | 4,614,000 | 1,768,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 249,728,000 | 253,215,000 | 253,538,000 |
| Total Liabilities | 173,092,000 | 177,485,000 | 178,156,000 |
| Total Stockholders Equity | 76,461,000 | 75,560,000 | 75,214,000 |
| Total Debt | 79,385,000 | 82,920,000 | 79,950,000 |
| Cash and Cash Equivalents | 8,196,000 | 8,586,000 | 8,453,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 13,426,000 | 9,107,000 | 10,639,000 |
| Capital Expenditure | -3,031,000 | -2,781,000 | -2,832,000 |
| Free Cash Flow | 10,395,000 | 6,326,000 | 7,807,000 |
| Net Income | 8,368,000 | 4,586,000 | 1,768,000 |
| Net Change in Cash | -4,780,000 | 359,000 | -172,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Full Access | Full Access | Full Access | Full Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 485,366,253.301 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (High) | 513,473,273.915 | Full Access | Full Access | Full Access | Full Access |
| Estimated Revenue (Avg) | 496,294,333.333 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Low) | 20,421,937.120 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (High) | 21,604,548.815 | Full Access | Full Access | Full Access | Full Access |
| Estimated Ebitda (Avg) | 20,881,739.510 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Low) | 14,984,149.471 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (High) | 16,119,838.812 | Full Access | Full Access | Full Access | Full Access |
| Estimated Net Income (Avg) | 15,425,707.582 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Low) | 10,735,344.510 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (High) | 11,357,016.386 | Full Access | Full Access | Full Access | Full Access |
| Estimated SGA Expense (Avg) | 10,977,052.093 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Avg) | 12.140 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (High) | 12.680 | Full Access | Full Access | Full Access | Full Access |
| Estimated EPS (Low) | 11.790 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated Revenue) | 7 | Full Access | Full Access | Full Access | Full Access |
| Number of Analysts (Estimated EPS) | 4 | Full Access | Full Access | Full Access | Full Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
Strengths (preview)
- CVS Health maintains a diversified revenue base across pharmacy services, retail, and healthcare segments, supported by consistent operating cash flow generation as indicated in cash flow statement columns.
- Strategic initiatives highlighted in the Q4 2024 earnings call target margin expansion and operational efficiency, contributing to adjusted EPS delivery amid industry pressures.
- Solid balance sheet metrics, including retained earnings and total assets, provide capacity for ongoing capital expenditures and dividend payments.
Log in with Full Access for Weaknesses, Opportunities, Threats, and the complete SWOT.
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates CVS intrinsic value between $29.93 – $73.76 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about CVS valuation
Is CVS Health Corporation (CVS) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for CVS Health Corporation (CVS) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is CVS a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether CVS trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is CVS’s P/E ratio?
You can see CVS’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for CVS?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is CVS a good long-term investment?
Whether CVS fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
CVS
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-0.02
Trading Metrics:
| Open: | 96.7 | Previous Close: | 97.08 | |
| Day Low: | 95.92 | Day High: | 97.52 | |
| Year Low: | 58.5 | Year High: | 98.43 | |
| Price Avg 50: | 84.58 | Price Avg 200: | 79.12 | |
| Volume: | 6.001M | Average Volume: | 7.89M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's freeCVS full analysis
Hey everyone, welcome back to the channel. Today we're diving deep into CVS Health, one of the biggest players in the healthcare space, and breaking down whether the stock still offers real value after its recent earnings beat and raised guidance. CVS has been on a roll lately with its insurance business finally showing signs of stability, and that's helped the whole portfolio turn a corner. The company just posted strong first-quarter results that beat estimates across pharmacy, retail, and…
